Sodium-glucose cotransporter-2 inhibitors and mortality and liver-related outcomes in patients with alcoholic cirrhosis, type 2 diabetes, and obesity.
文献摘要
Introduction and objectives Sodium-glucose co-transporter 2 inhibitors (SGLT2-i 1 ) improve cardiovascular and renal outcomes in type 2 diabetes mellitus, but their safety and clinical impact in advanced liver disease remain uncertain because patients with cirrhosis were underrepresented in major trials. Materials and methods Using the TriNetX research network, we identified adults with alcoholic cirrhosis, type 2 diabetes, and obesity and compared outcomes according to SGLT2-i exposure. After 1:1 propensity score matching, 5,128 matched pairs were analyzed. The primary outcome was all-cause mortality; secondary outcomes included all-cause hospitalization, ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and variceal bleeding. Results In the matched cohort, SGLT2-i use was associated with lower all-cause mortality (HR, 0.71; 95% CI, 0.66 to 0.78), hospitalization (HR, 0.84; 95% CI, 0.80 to 0.89), ascites (HR, 0.72; 95% CI, 0.67 to 0.77), spontaneous bacterial peritonitis (HR, 0.74; 95% CI, 0.62 to 0.87), and variceal bleeding (HR, 0.82; 95% CI, 0.67 to 0.99), with no difference in hepatic encephalopathy. Conclusions Among patients with alcoholic cirrhosis, type 2 diabetes, and obesity, SGLT2-i use was associated with improved survival and fewer liver-related complications.